CTKB logo

Cytek Biosciences, Inc. Stock Price

NasdaqGS:CTKB Community·US$505.1m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 6 Fair Values set on narratives written by author

CTKB Share Price Performance

US$3.97
-1.10 (-21.70%)
50.4% undervalued intrinsic discount
US$8.00
Fair Value
US$3.97
-1.10 (-21.70%)
50.4% undervalued intrinsic discount
US$8.00
Fair Value
Price US$3.97
AnalystHighTarget US$8.00
AnalystConsensusTarget US$5.13
AnalystLowTarget US$4.00

CTKB Community Narratives

AnalystHighTarget·Updated
Fair Value US$8 50.4% undervalued intrinsic discount

Growing Global Healthcare Investment And AI Will Advance Cytometry Adoption

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·Updated
Fair Value US$5.13 22.5% undervalued intrinsic discount

Cloud Software And Flow Cytometry Will Unlock Global Opportunity

0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AnalystLowTarget·Updated
Fair Value US$4 0.8% undervalued intrinsic discount

Rising Costs And Trade Tensions Will Shrink Flow Cytometry Markets

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent CTKB News & Updates

Cytek Biosciences, Inc. (NASDAQ:CTKB) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Aug 15
Cytek Biosciences, Inc. (NASDAQ:CTKB) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Is Cytek Biosciences (NASDAQ:CTKB) Using Debt Sensibly?

Jul 28
Is Cytek Biosciences (NASDAQ:CTKB) Using Debt Sensibly?
User avatar

APAC Markets And Recurring Revenues Will Support Life Sciences

Growth in Asia-Pacific and strong recurring revenues from services and reagents offset weaker performance in the US and Europe, supporting long-term stability.

Cytek Biosciences, Inc. Key Details

US$196.0m

Revenue

US$89.4m

Cost of Revenue

US$106.7m

Gross Profit

US$113.1m

Other Expenses

-US$6.4m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-0.05
Gross Margin
54.42%
Net Profit Margin
-3.27%
Debt/Equity Ratio
1.7%

Cytek Biosciences, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Excellent balance sheet and slightly overvalued.

2 Risks
0 Rewards

About CTKB

Founded
1992
Employees
688
CEO
Wenbin Jiang
WebsiteView website
cytekbio.com

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. The company offers aurora and northern lights systems delivers cell analysis; aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; enhanced small particle detection; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. It serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. The company distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

U.S. Market Performance

  • 7 Days: 1.2%
  • 3 Months: 8.5%
  • 1 Year: 17.7%
  • Year to Date: 14.8%
The market is up 1.2% over the last week, with the Information Technology sector leading the way, up 2.4%. In the last year, the market has climbed 18%. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›